Dimeric ORF2.1 antigen of hepatitis E virus




Figure 1

Multimeric antigen of hepatitis A virus




Figure 2

PCT/AU2004/001522

3/8

Virus-like particle (VLP) of duck hepatitis B virus.

A. Use of anti-DHBV bridge




Figure 3

Inventors: David Andrew Anderson et al.

Docket: 19808

PCT/AU 2004/001522

4/8

Virus-like particle (VLP) of duck hepatitis B virus.

B Use of anti-analyte bridge




Figure 4

Inventors: David Andrew Anderson et al.

Docket: 19808

PCT/A1/2004/001522

5/8

Monomeric antigen with second binding site as bridge.

A. Use of second epitope on the analyte antigen




Figure 5

VO 2005/045439

6/8

Monomeric antigen with second binding site as bridge.

B. Use of fusion protein such as MBP with analyte antigen




Figure 6

Monomeric antigen with ligand binding site as bridge.




Figure 7

Multimeric antigen of hepatitis A virus.




Figure 8